NeurAxis, Inc.
NRXSHealthcare|Biotechnology|US
$6.24
+0.13 (+2.13%)
Tangible Book / Share
$0.53
Cash / Share
$0.69
About
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Stock Price
+146.6%(1Y)
1M
-7.8%
3M
-12.0%
6M
-23.9%
YTD
+37.4%
1Y
+143.8%
3Y
+156.8%
5Y
+4.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$78.4M
Employees24 (+14% YoY)
CEOBrian Carrico
IPO DateAug 9, 2023
Beta1.38
52-Week Range$2.21 – $9.33
Avg Volume116,873
ExchangeAMEX
Websiteneuraxis.com
Ownership
Float68.1%
Shares Outstanding12.6M
Recent Insider Trades
Carrico Brian AllenBUY
Oct 8, 2026268 shares @ $4.84
Carrico Thomas JoesephBUY
Oct 8, 2026328 shares @ $4.84
Henrichs Timothy RobertBUY
Oct 8, 20261,937 shares @ $4.84
Blanchard Craig ThomasOTHER
Sep 28, 20260 shares
Carrico Thomas JoesephAWARD
Aug 24, 2026306,236 shares
Peers
CLGNCollPlant Biotechnologies Ltd.
$7.5MCVKDCadrenal Therapeutics, Inc. Common Stock
$3.5MENLVEnlivex Therapeutics Ltd.
$21.4MKLTOKlotho Neurosciences, Inc.
$20.1MNERVMinerva Neurosciences, Inc.
$115.5MNRSNNeuroSense Therapeutics Ltd.
$3.2MRLYBRallybio Corporation
$84.8MSONNSonnet BioTherapeutics Holdings, Inc.
$8.4MRecent News
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
Oct 27, 2026 · globenewswire.com
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
Oct 15, 2026 · globenewswire.com
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)
Oct 12, 2026 · defenseworld.net
Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)
Oct 5, 2026 · defenseworld.net
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
Sep 29, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:24 AM